{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Padoporfin",
  "nciThesaurus": {
    "casRegistry": "274679-00-4",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A novel palladium-substituted bacteriochlorophyll derivative and photosensitizer with potential antitumor activity. Upon administration, inactive padoporfin is activated locally when the tumor bed is exposed to photoirradiation; the activated form induces local cytotoxic processes, resulting in local tissue damage, disruption of tumor vasculature, and tumor hypoxia and necrosis.",
    "fdaUniiCode": "OIH1H7CJCJ",
    "identifier": "C61321",
    "preferredName": "Padoporfin",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1420",
      "C1742"
    ],
    "synonyms": [
      "(Hydrogen 3-((2(sup 2)R,7R,8R,17S,18S)-12-acetyl-7-ethyl-2(sup 2)-(methoxycarbonyl)-3,8,13,17-tetramethyl-2(sup 1)-oxo-2(sup 1),2(sup 2),7,8,17,18-hexahydrocyclopenta(at)porphyrin-18-yl)propanoato-kappa4N(sup 21),N(sup 22),N(sup 23),N(sup 24))palladium",
      "PADOPORFIN",
      "Padoporfin",
      "Tookad",
      "WST09"
    ]
  }
}